Labcorp Holdings Inc. $LH Stock Purchased by Yousif Capital Management LLC

Yousif Capital Management LLC boosted its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 23.6% during the third quarter, Holdings Channel reports. The firm owned 10,421 shares of the medical research company’s stock after buying an additional 1,992 shares during the quarter. Yousif Capital Management LLC’s holdings in Labcorp were worth $3,211,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in Labcorp by 1.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock valued at $607,241,000 after acquiring an additional 22,170 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Labcorp by 2.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock valued at $355,569,000 after acquiring an additional 28,584 shares in the last quarter. Royal Bank of Canada increased its holdings in Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after acquiring an additional 133,549 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Labcorp during the second quarter worth about $168,222,000. Finally, Bessemer Group Inc. raised its position in Labcorp by 47.3% during the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock worth $154,493,000 after acquiring an additional 185,847 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LH. Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, October 21st. Barclays increased their price target on shares of Labcorp from $320.00 to $330.00 and gave the company an “equal weight” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. Finally, Mizuho set a $355.00 target price on Labcorp in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.

Labcorp Price Performance

NYSE:LH opened at $329.51 on Tuesday. The firm has a market cap of $26.72 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.87. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average is $320.76 and its two-hundred day moving average is $285.21. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $341.80.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Research analysts expect that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is 23.82%.

Insider Activity

In other news, CEO Adam Schechter sold 4,669 shares of Labcorp stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the completion of the sale, the chief executive officer owned 102,565 shares of the company’s stock, valued at $32,858,749.05. The trade was a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kerrii Anderson sold 3,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the transaction, the director owned 6,563 shares of the company’s stock, valued at $2,087,165.26. The trade was a 31.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,593 shares of company stock valued at $2,733,295 over the last quarter. Company insiders own 0.84% of the company’s stock.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.